Abeona Therapeutics Inc. (ABEO)
| Market Cap | 147.57M |
| Revenue (ttm) | 10.00M |
| Net Income (ttm) | -84.23M |
| Shares Out | 92.66M |
| EPS (ttm) | -0.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $1.49 |
| Previous Close | $1.50 |
| Change ($) | -0.01 |
| Change (%) | -0.67% |
| Day's Open | 1.50 |
| Day's Range | 1.43 - 1.52 |
| Day's Volume | 1,579,434 |
| 52-Week Range | 0.99 - 3.79 |
Refreshed board to bring fresh perspectives, relevant expertise and diverse experience Refreshed board to bring fresh perspectives, relevant expertise and diverse experience
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -88.89% and -45.95%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Fourth patient treated in pivotal Phase 3 VIITAL™ study of EB-101 in RDEB after successful Type B meeting with FDA
NEW YORK, March 23, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty c...
CEO appointment provides continuity and reflects company's demonstrated strong operational performance CEO appointment provides continuity and reflects company's demonstrated strong operational performance
NEW YORK and CLEVELAND, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company will present at th...
In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained redu...
NEW YORK and CLEVELAND, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it will host a live webinar fo...
Clinical trial amendment successfully completed for co-primary endpoints of partial wound closure and mean pain reduction Clinical trial amendment successfully completed for co-primary endpoints of part...
Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.
NEW YORK and CLEVELAND, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that abstracts detailing new interi...
Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.
Abeona Therapeutics Inc's (NASDAQ: ABEO) stock does not reflect the company's in-house manufacturing capabilities and pipeline, according to Cantor Fitzgerald. The Abeona Therapeutics Analyst: Kristen K...
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of 38.46% and 0.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET
NEW YORK and CLEVELAND, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Senior Vice P...
Steven H. Rouhandeh Appointed as Chairman of the Board of Directors
NEW YORK and CLEVELAND, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced changes in its executive leaders...
NEW YORK and CLEVELAND, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company will participat...
NEW YORK and CLEVELAND and DALLAS, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, and Taysha Gene Therapies, a patient-c...
Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs
NEW YORK and CLEVELAND, July 10, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two poster presentations rel...
Abeona (ABEO) restarts patient enrollment in phase III VIITAL study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.
To lead Abeona’s commercial organization, EB-101 commercialization planning and pre-commercial strategy for AAV-based gene therapy programs To lead Abeona’s commercial organization, EB-101 commercializa...
NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical pr...
NEW YORK and CLEVELAND, June 18, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two abstracts related to its...
NEW YORK and CLEVELAND, June 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced Board of Director appointments th...
Is (ABEO) Outperforming Other Medical Stocks This Year?
Abeona Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Abeona's (ABEO) operating expenses are expected to have increased in the first quarter driven by clinical studies on its lead gene therapy candidate.
NEW YORK and CLEVELAND, April 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced it granted options to Brian Pere...
As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.
Company appoints experienced industry leaders Brian Pereira as Executive Chairman and Shawn Tomasello as Independent Board Member Company appoints experienced industry leaders Brian Pereira as Executive...
Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.
Abeona Therapeutics (ABEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
NEW YORK and CLEVELAND, March 27, 2020 (GLOBE NEWSWIRE) -- The COVID-19 pandemic has created extraordinary challenges across all aspects of healthcare. Many institutions and their brave staff of provi...
Abeona Therapeutics (ABEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Abeona (ABEO) treats first patient in a pivotal study evaluating its gene-corrected cell therapy, EB-101, as a treatment for recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder.
Majority of potential study participants have been pre-screened
Can these high-flying biotech stocks keep up their sizzling momentum?
Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.
The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.
As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.
Neurocognitive development of young MPS IIIA patients preserved up to two years post ABO-102 treatment
NEW YORK and CLEVELAND, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the United States Patent and...
Study open for enrollment and patient screening underway at Stanford University
Abeona Therapeutics: Speculative Buy After Financing
NEW YORK and CLEVELAND, Dec. 24, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the closing of its underwritten p...
The small-cap company announced the pricing of a public stock offering.
Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.
About ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for th... [Read more...]
| Industry Biotechnology | IPO Date Sep 19, 1980 |
| CEO Joao Siffert | Employees 76 |
| Stock Exchange NASDAQ | Ticker Symbol ABEO |
Analyst Forecasts
According to 5 analysts, the average rating for ABEO stock is "Buy." The 12-month stock price forecast is 5.67, which is an increase of 280.54% from the latest price.